Cancer chemotherapy and pharmacology · 2025
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balis Frank M, Rieger Elizabeth, Bunin Nancy J, Gardiner JoAnn, Shaw Leslie M, Olson Timothy S, Milone Michael C
Аннотация
PURPOSE: Apply population pharmacokinetic modeling to a single institution busulfan therapeutic drug monitoring (TDM) data set from infants and children to refine dosing methods.
METHODS: One-compartment pharmacokinetic model was fit to busulfan TDM data from 328 infants and children with malignant and non-malignant diseases treated with busulfan-containing transplant conditioning regimens. Age-dependence of busulfan clearance scaled to body weight and body surface area (BSA) was compared, and busulfan AUC was simulated for a BSA-scaled dose of 100 mg/m2 combined with a BSA-banded dosing table for infants and children with a BSA < 0.5 m2.
RESULTS: Busulfan clearance scaled to body weight is age-dependent. Clearance in children ≤ 3 years (0.234 L/[h•kg]) is higher than the typical value for the population, (0.205 L/[h•kg]), and 48% of children < 5 years have subtherapeutic busulfan AUCs after the first dose. Busulfan clearance scaled to BSA (typical value, 5.47 L/[h•m2]) is more uniform across the pediatric age span, except for infants (≤ 1 year, 4.27 L/[h•m2]). Simulated busulfan AUCs with a dose of 100 mg/m2 for patients with a BSA ≥ 0.5 m2 combined with a BSA-banded dosing table for patients with a BSA < 0.5 m2 achieved a therapeutic AUC after the first dose in 49% more patients than body weight scaled doses.
CONCLUSION: Our model predicts a greater proportion of children would achieve a therapeutic busulfan AUC after the first dose with a dose of 100 mg/m2/d combined with the infant dosing table for patients with a BSA < 0.5 m2 compared to body weight-scaled dosing.
METHODS: One-compartment pharmacokinetic model was fit to busulfan TDM data from 328 infants and children with malignant and non-malignant diseases treated with busulfan-containing transplant conditioning regimens. Age-dependence of busulfan clearance scaled to body weight and body surface area (BSA) was compared, and busulfan AUC was simulated for a BSA-scaled dose of 100 mg/m2 combined with a BSA-banded dosing table for infants and children with a BSA < 0.5 m2.
RESULTS: Busulfan clearance scaled to body weight is age-dependent. Clearance in children ≤ 3 years (0.234 L/[h•kg]) is higher than the typical value for the population, (0.205 L/[h•kg]), and 48% of children < 5 years have subtherapeutic busulfan AUCs after the first dose. Busulfan clearance scaled to BSA (typical value, 5.47 L/[h•m2]) is more uniform across the pediatric age span, except for infants (≤ 1 year, 4.27 L/[h•m2]). Simulated busulfan AUCs with a dose of 100 mg/m2 for patients with a BSA ≥ 0.5 m2 combined with a BSA-banded dosing table for patients with a BSA < 0.5 m2 achieved a therapeutic AUC after the first dose in 49% more patients than body weight scaled doses.
CONCLUSION: Our model predicts a greater proportion of children would achieve a therapeutic busulfan AUC after the first dose with a dose of 100 mg/m2/d combined with the infant dosing table for patients with a BSA < 0.5 m2 compared to body weight-scaled dosing.